Skip to main content
. 2021 Apr 12;42(6):2273–2281. doi: 10.1007/s10072-021-05231-0

Table 1.

COVID 19 encephalopathy: pathogenetic hypotheses

Clinical features Mechanism Course Management Outcome Putative neuropathological findings
Secondary CNS damage Not specific: fever, consciousness disorder, delirium Indirect effect (fever, hypoxia, ischemia/hemorrhage, metabolic derangement, sepsis, toxins, concurrent conditions) Acute/subacute General measures: ventilatory support, O2, sedation, antibiotics, etc Variable Hypoxic and ischemic injuries
Direct CNS invasion Not specific: confusion to coma, headache, seizures Direct invasion of the CNS by SARS-CoV-2 Acute Symptomatic therapy: steroids, antiepileptics, etc Unknown (few reports) SARS-CoV-2 RNA and proteins (rare) not associated with the severity of neuropathological changes
Immunomediate reaction to the virus Prevalent “Frontal” symptoms and language impairment Cytokine-mediated neuroinflammatory process Few days Immunotherapy Reversal/attenuation Mild abnormalities with inflammation by diffuse astrocytes and microglia activation and infiltration of cytotoxic T lymphocytes